猫咪AV成人 to attend the JP Morgan 2020 Healthcare Conference in San Francisco, January 12-16, 2020
CAMBRIDGE, UK and NEW YORK, NEW YORK, 06 January 2020 鈥�听猫咪AV成人 Limited (猫咪AV成人), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the company will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
The management team will be in attendance and hosting meetings with partners and investors.
END
听For more information, please contact:
猫咪AV成人 Ltd.
Niall Martin, Chief Executive Officer
Tel: +44 (0)1223 804180
听
Media & IR Enquiries
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Tel: +44 (0) 203 950 9144
听
Notes to Editors
听
About 猫咪AV成人 Limited
猫咪AV成人 is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and the National Centre for Biomolecular Research at Masaryk University in the Czech Republic. 猫咪AV成人 is building a pipeline of next-generation DDR programmes to target hard to treat cancers. Backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix, Pfizer Ventures, ipgroup, SV Healthcare and M Ventures.